Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer
Status:
Unknown status
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Capecitabine is an orally administered fluoropyrimidine that is converted by 5-FU by
thymidine phosphorylase (TP), preferentially in tumor tissues and has demonstrated activity
as single agent in patients with gastrointestinal cancer. Up-regulation of TP after taxane
treatment in vitro suggested that there may be synergistic effects in combined treatment with
taxane and capecitabine. The combination of taxane and capecitabine was reported to be highly
active against non-small cell lung cancer, breast cancer, and stomach cancer.